Meet Some of the Physicians
and Cervical Spinal Cord
Injury Patients in the
AST-OPC1 Clinical Trial

News Releases

Click here to sign up and receive email notifications of new press releases.

April 26, 2016
Asterias Biotherapeutics to Present at Stem Cell Summit 2016

FREMONT, Calif., April 26, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that Katharine Spink, Ph.D., Chief Operating Officer, will present at the Stem Cell Summit 2016 to be held on April 25-27, 2016 in Boston, MA. Dr. Spink will provide an overview of the Asterias AST-OPC1 (oligodendrocyte progenitor cells) therapeutic development program that is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury.

Presentation Details 


Stem Cell Summit 2016

Conference 2: Stem Cell Product Development & Commercialization 


Wednesday, April 27, 2016


9:40 a.m. EDT


Hyatt Regency, Boston, MA

The title of Dr. Spink's presentation is "AST-OPC1: Clinical Development of a Novel Cellular Therapeutic for Spinal Cord Injury." The presentation will be available on Asterias' website at

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies.  Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology. AST-VAC1 (antigen-presenting autologous dendritic cells) demonstrated promise in a Phase 2 study in acute myelogenous leukemia (AML) and completed a successful end-of-Phase 2 meeting with the FDA in advance of initiating planning for a single pivotal Phase 3 AML study.  AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic immunotherapy. The company's research partner, Cancer Research UK, plans to begin a Phase 1/2 clinical trial of AST-VAC2 in non-small cell lung cancer in 2017.  AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. Additional information about Asterias can be found at

To view the original version on PR Newswire, visit:

SOURCE Asterias Biotherapeutics, Inc.

Asterias Biotherapeutics Tel: (510) 456-3800